Clinical Cancer Research, Vol 3, Issue 11 2099-2106, Copyright © 1997 by American Association for Cancer Research

ARTICLES

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner

M Bos, J Mendelsohn, YM Kim, J Albanell, DW Fry and J Baselga
Laboratory of Receptor Biology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

PD153035 is reported to be a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase and, to a lesser degree, of the closely related HER2/neu receptor. We show that PD153035 inhibits EGF-dependent EGF receptor phosphorylation and suppresses the proliferation and clonogenicity of a wide panel of EGF receptor-overexpressing human cancer cell lines. EGF receptor autophosphorylation in response to exogenous EGF was completely inhibited at PD153035 concentrations of >75 nM in cells overexpressing the EGF receptor. In contrast, PD153035 only reduced heregulin-dependent tyrosine phosphorylation in HER2/neu-overexpressing cell lines at significantly higher concentrations (1400-2800 nM). PD153035 exposure did not affect the expression of either EGF receptors or HER2/neu. PD153035 caused a dose-dependent growth inhibition of EGF receptor-overexpressing cell lines at low micromolar concentrations, and the IC50 in monolayer cultures was less than 1 microM in most cell lines tested. At doses of up to 2.5 microM, the IC50 for HER2/neu-overexpressing cells was not reached. In colony-forming assays, the PD153035 growth-inhibitory activity in cultures driven by endogenous (autocrine) ligand was correlated with EGF receptor number, with higher activity in cells expressing higher numbers of EGF receptors and only minimal activity in cells expressing normal numbers of EGF receptors but high HER2/neu levels. PD153053 also abolished all growth effects mediated by the addition of exogenous EGF; this condition could be reversed upon removal of the compound. Cotreatment with C225, an anti-EGF receptor-blocking monoclonal antibody, further enhanced the antitumor activity of PD153035, suggesting mechanisms of action for C225 other than competition with ligand binding. This latter finding also suggests that combined anti-EGF receptor strategies may be of enhanced benefit against tumors with high levels of EGF receptor expression.

This article has been cited by other articles:

				D. J. Chen and C. S. Nirodi The Epidermal Growth Factor Receptor: A Role in Repair of Radiation-Induced DNA Damage Clin. Cancer Res., November 15, 2007; 13(22): 6555 - 6560. [Abstract] [Full Text] [PDF]

				T. G. Johns, R. M. Perera, S. C. Vernes, A. A. Vitali, D. X. Cao, W. K. Cavenee, A. M. Scott, and F. B. Furnari The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization Clin. Cancer Res., March 15, 2007; 13(6): 1911 - 1925. [Abstract] [Full Text] [PDF]

				F. Rojo, L. Najera, J. Lirola, J. Jimenez, M. Guzman, M. D. Sabadell, J. Baselga, and S. R. y Cajal 4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis Clin. Cancer Res., January 1, 2007; 13(1): 81 - 89. [Abstract] [Full Text] [PDF]

				M. P. Cunningham, H. Thomas, Z. Fan, and H. Modjtahedi Responses of Human Colorectal Tumor Cells to Treatment with the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ICR62 Used Alone and in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib. Cancer Res., August 1, 2006; 66(15): 7708 - 7715. [Abstract] [Full Text] [PDF]

				Y. Zhou and M. G. Brattain Synergy of Epidermal Growth Factor Receptor Kinase Inhibitor AG1478 and ErbB2 Kinase Inhibitor AG879 in Human Colon Carcinoma Cells Is Associated with Induction of Apoptosis Cancer Res., July 1, 2005; 65(13): 5848 - 5856. [Abstract] [Full Text] [PDF]

				G. W. Cole Jr, A. M. Alleva, R. M. Reddy, J. B. Maxhimer, J. Zuo, D. S. Schrump, and D. M. Nguyen The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1010 - 1017. [Abstract] [Full Text] [PDF]

				C. D. Woodworth, E. Michael, D. Marker, S. Allen, L. Smith, and M. Nees Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment Mol. Cancer Ther., April 1, 2005; 4(4): 650 - 658. [Abstract] [Full Text] [PDF]

				P. Matar, F. Rojo, R. Cassia, G. Moreno-Bueno, S. Di Cosimo, J. Tabernero, M. Guzman, S. Rodriguez, J. Arribas, J. Palacios, et al. Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority Over Single-Agent Receptor Targeting Clin. Cancer Res., October 1, 2004; 10(19): 6487 - 6501. [Abstract] [Full Text] [PDF]

				L. Castillo, M. C. Etienne-Grimaldi, J. L. Fischel, P. Formento, N. Magne, and G. Milano Pharmacological background of EGFR targeting Ann. Onc., July 1, 2004; 15(7): 1007 - 1012. [Abstract] [Full Text] [PDF]

				J-L Yang, X-J Qu, P J Russell, and D Goldstein Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon {alpha} Gut, January 1, 2004; 53(1): 123 - 129. [Abstract] [Full Text] [PDF]

				T. G. Johns, R. B. Luwor, C. Murone, F. Walker, J. Weinstock, A. A. Vitali, R. M. Perera, A. A. Jungbluth, E. Stockert, L. J. Old, et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478 PNAS, December 23, 2003; 100(26): 15871 - 15876. [Abstract] [Full Text] [PDF]

				L. Gunaratnam, M. Morley, A. Franovic, N. de Paulsen, K. Mekhail, D. A. E. Parolin, E. Nakamura, I. A. J. Lorimer, and S. Lee Hypoxia Inducible Factor Activates the Transforming Growth Factor-{alpha}/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells J. Biol. Chem., November 7, 2003; 278(45): 44966 - 44974. [Abstract] [Full Text] [PDF]

				H. Shao, H. Y. Cheng, R. G. Cook, and D. J. Tweardy Identification and Characterization of Signal Transducer and Activator of Transcription 3 Recruitment Sites within the Epidermal Growth Factor Receptor Cancer Res., July 15, 2003; 63(14): 3923 - 3930. [Abstract] [Full Text] [PDF]

				J. Mendelsohn and J. Baselga Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer J. Clin. Oncol., July 15, 2003; 21(14): 2787 - 2799. [Abstract] [Full Text] [PDF]

				M. L. Janmaat, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells: Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways Clin. Cancer Res., June 1, 2003; 9(6): 2316 - 2326. [Abstract] [Full Text] [PDF]

				C. L. Arteaga and J. Baselga Clinical Trial Design and End Points for Epidermal Growth Factor Receptor-targeted Therapies: Implications for Drug Development and Practice Clin. Cancer Res., May 1, 2003; 9(5): 1579 - 1589. [Full Text] [PDF]

				J. Anido, P. Matar, J. Albanell, M. Guzman, F. Rojo, J. Arribas, S. Averbuch, and J. Baselga ZD1839, a Specific Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Induces the Formation of Inactive EGFR/HER2 and EGFR/HER3 Heterodimers and Prevents Heregulin Signaling in HER2-overexpressing Breast Cancer Cells Clin. Cancer Res., April 1, 2003; 9(4): 1274 - 1283. [Abstract] [Full Text] [PDF]

				M. C. BURESI, A. G. BURET, M. D. HOLLENBERG, and W. K. MacNAUGHTON Activation of proteinase-activated receptor 1 stimulates epithelial chloride secretion through a unique MAP kinase- and cyclo-oxygenase-dependent pathway FASEB J, October 1, 2002; 16(12): 1515 - 1525. [Abstract] [Full Text] [PDF]

				J. Mendelsohn Targeting the Epidermal Growth Factor Receptor for Cancer Therapy J. Clin. Oncol., September 15, 2002; 20(90001): 1s - 13. [Full Text] [PDF]

				J. N. Myers, F. C. Holsinger, B. N. Bekele, E. Li, S. A. Jasser, J. J. Killion, and I. J. Fidler Targeted Molecular Therapy for Oral Cancer With Epidermal Growth Factor Receptor Blockade: A Preliminary Report Arch Otolaryngol Head Neck Surg, August 1, 2002; 128(8): 875 - 879. [Abstract] [Full Text] [PDF]

				T. Sorkina, F. Huang, L. Beguinot, and A. Sorkin Effect of Tyrosine Kinase Inhibitors on Clathrin-coated Pit Recruitment and Internalization of Epidermal Growth Factor Receptor J. Biol. Chem., July 19, 2002; 277(30): 27433 - 27441. [Abstract] [Full Text] [PDF]

				M. Fujimura, T. Hidaka, and S. Saito Selective Inhibition of the Epidermal Growth Factor Receptor by ZD1839 Decreases the Growth and Invasion of Ovarian Clear Cell Adenocarcinoma Cells Clin. Cancer Res., July 1, 2002; 8(7): 2448 - 2454. [Abstract] [Full Text] [PDF]

				V. Smith, M. G. Rowlands, E. Barrie, P. Workman, and L. R. Kelland Establishment and Characterization of Acquired Resistance to the Farnesyl Protein Transferase Inhibitor R115777 in a Human Colon Cancer Cell Line Clin. Cancer Res., June 1, 2002; 8(6): 2002 - 2009. [Abstract] [Full Text] [PDF]

				R. B. Robey, J. Ma, A. V. P. Santos, O. A. Noboa, P. E. Coy, and J. M. Bryson Regulation of Mesangial Cell Hexokinase Activity and Expression by Heparin-binding Epidermal Growth Factor-like Growth Factor. EPIDERMAL GROWTH FACTORS AND PHORBOL ESTERS INCREASE GLUCOSE METABOLISM VIA A COMMON MECHANISM INVOLVING CLASSIC MITOGEN-ACTIVATED PROTEIN KINASE PATHWAY ACTIVATION AND INDUCTION OF HEXOKINASE II EXPRESSION J. Biol. Chem., April 19, 2002; 277(17): 14370 - 14378. [Abstract] [Full Text] [PDF]

				N. Normanno, M. Campiglio, A. De Luca, G. Somenzi, M. Maiello, F. Ciardiello, L. Gianni, D. S. Salomon, and S. Menard Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth Ann. Onc., January 19, 2002; 13(1): 65 - 72. [Abstract] [Full Text] [PDF]

				J. Albanell, F. Rojo, S. Averbuch, A. Feyereislova, J. M. Mascaro, R. Herbst, P. LoRusso, D. Rischin, S. Sauleda, J. Gee, et al. Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition J. Clin. Oncol., January 1, 2002; 20(1): 110 - 124. [Abstract] [Full Text] [PDF]

				Y. Zhang, G. Liu, and Z. Dong MSK1 and JNKs Mediate Phosphorylation of STAT3 in UVA-irradiated Mouse Epidermal JB6 Cells J. Biol. Chem., November 2, 2001; 276(45): 42534 - 42542. [Abstract] [Full Text] [PDF]

				J. Albanell, J. Codony-Servat, F. Rojo, J. M. Del Campo, S. Sauleda, J. Anido, G. Raspall, J. Giralt, J. Rosello, R. I. Nicholson, et al. Activated Extracellular Signal-regulated Kinases: Association with Epidermal Growth Factor Receptor/Transforming Growth Factor {alpha} Expression in Head and Neck Squamous Carcinoma and Inhibition by Anti-Epidermal Growth Factor Receptor Treatments Cancer Res., September 1, 2001; 61(17): 6500 - 6510. [Abstract] [Full Text] [PDF]

				M. Hidalgo, L. L. Siu, J. Nemunaitis, J. Rizzo, L. A. Hammond, C. Takimoto, S. G. Eckhardt, A. Tolcher, C. D. Britten, L. Denis, et al. Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies J. Clin. Oncol., July 1, 2001; 19(13): 3267 - 3279. [Abstract] [Full Text] [PDF]

				G. Jones, J. Machado Jr., and A. Merlo Loss of Focal Adhesion Kinase (FAK) Inhibits Epidermal Growth Factor Receptor-dependent Migration and Induces Aggregation of NH2-Terminal FAK in the Nuclei of Apoptotic Glioblastoma Cells Cancer Res., July 1, 2001; 61(13): 4978 - 4981. [Abstract] [Full Text] [PDF]

				G. Lammering, T. H. Hewit, W. T. Hawkins, J. N. Contessa, D. B. Reardon, P.-S. Lin, K. Valerie, P. Dent, R. B. Mikkelsen, and R. K. Schmidt-Ullrich Epidermal Growth Factor Receptor as a Genetic Therapy Target for Carcinoma Cell Radiosensitization J Natl Cancer Inst, June 20, 2001; 93(12): 921 - 929. [Abstract] [Full Text] [PDF]

				F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico, S. De Placido, A. R. Bianco, and G. Tortora Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor Clin. Cancer Res., May 1, 2000; 6(5): 2053 - 2063. [Abstract] [Full Text]

				P. A. Bunn Jr., A. Soriano, G. Johnson, and L. Heasley New Therapeutic Strategies for Lung Cancer : Biology and Molecular Biology Come of Age Chest, April 1, 2000; 117(4_suppl_1): 163S - 168S. [Abstract] [Full Text] [PDF]